Treatment of BRAF V600-mutated melanomas with a RAF inhibitor, such as dabrafenib, results in rapid adaptations including loss of MAPK pathway feedback inhibition (1, 2) and an increase in oxidative phosphorylation (oxphos; refs. 3–5). The gene discussed is BRAF; the disease is melanoma.